Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Involved-field radiotherapy for advanced Hodgkin's lymphoma.
Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van 't Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M; European Organization for Research and Treatment of Cancer Lymphoma Group. Aleman BM, et al. Among authors: carde p. N Engl J Med. 2003 Jun 12;348(24):2396-406. doi: 10.1056/NEJMoa022628. N Engl J Med. 2003. PMID: 12802025 Free article. Clinical Trial.
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H, Aleman BM, Bosq J, Vovk M, Verschueren TA, Pény AM, Girinsky T, Raemaekers JM, Henry-Amar M. Noordijk EM, et al. Among authors: carde p. J Clin Oncol. 2006 Jul 1;24(19):3128-35. doi: 10.1200/JCO.2005.05.2746. Epub 2006 Jun 5. J Clin Oncol. 2006. PMID: 16754934 Clinical Trial.
Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC, Kluin-Nelemans HC, Carde P, Meerwaldt JH, Tirelli U, Aleman BM, Baars J, Thomas J, van Glabbeke M, Noordijk EM. Moser EC, et al. Among authors: carde p. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1168-77. doi: 10.1016/j.ijrobp.2006.05.006. Epub 2006 Aug 2. Int J Radiat Oncol Biol Phys. 2006. PMID: 16887289
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Fermé C, et al. Among authors: carde p. N Engl J Med. 2007 Nov 8;357(19):1916-27. doi: 10.1056/NEJMoa064601. N Engl J Med. 2007. PMID: 17989384 Free article. Clinical Trial.
ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.
Fermé C, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, Lugtenburg PJ, Bouabdallah R, Carde P, Sebban C, Eghbali H, Salles G, van Imhoff GW, Thyss A, Noordijk EM, Reman O, Lybeert MLM, Janvier M, Spina M, Audhuy B, Raemaekers JMM, Delarue R, Anglaret B, de Weerdt O, Marjanovic Z, Tersteeg RJHA, de Jong D, Brière J, Henry-Amar M; European Organisation for Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des Lymphomes de l'Adulte. Fermé C, et al. Among authors: carde p. Eur J Cancer. 2017 Aug;81:45-55. doi: 10.1016/j.ejca.2017.05.005. Epub 2017 Jun 8. Eur J Cancer. 2017. PMID: 28601705 Clinical Trial.
Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
Raemaekers J, Burgers M, Henry-Amar M, Pinna A, Mandard A, Monfardini S, Hagenbeek A, Breed W, Carde P, Vovk M, van Hoof A, Thomas J, Noordijk E. Raemaekers J, et al. Among authors: carde p. Ann Oncol. 1997;8 Suppl 1:111-4. Ann Oncol. 1997. PMID: 9187443 Clinical Trial.
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, Raemaekers JM, van Hoof A, De Wolf-Peeters C, van Glabbeke M. Hagenbeek A, et al. Among authors: carde p. J Clin Oncol. 1998 Jan;16(1):41-7. doi: 10.1200/JCO.1998.16.1.41. J Clin Oncol. 1998. PMID: 9440721 Clinical Trial.
Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.
Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J, Bron D, Meerwaldt JH, van Glabbeke M, Raemaekers JM, Kluin-Nelemans HC. Moser EC, et al. Among authors: carde p. Clin Lymphoma Myeloma. 2005 Sep;6(2):122-30. doi: 10.3816/CLM.2005.n.038. Clin Lymphoma Myeloma. 2005. PMID: 16231850 Clinical Trial.
160 results